Abacavir (Ziagen): Research: 2003
- Reasons for Early Abacavir Discontinuation in HIV-Infected Patients (November 2003)
Abstract of a study in the Annals of Pharmacotherapy.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Clinical Risk Factors for Hypersensitivity Reactions to Abacavir: Side Effects of Antiretroviral Therapy (September 17, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Interim Analysis of Failure of Tenofovir/Abacavir/3TC Regimen (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Can Abacavir Be Given Once-a-Day? (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Emergence of Resistance-Associated Mutations Over 96 Weeks in Patients Initiating ABC/3TC + d4T, EFV or APV/r (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Abacavir Not Inferior to AZT in Treatment-Naive Patients (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
- Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients With Human Immunodeficiency Virus Infection (September 11, 2003)
In The New England Journal of Medicine
- Viread, Epivir and Ziagen Combination -- Failure in Naive Patients With a Once-Daily Regimen (September/October 2003)
Daniel S. Berger, M.D., chief investigator in study ESS30009, examines what went wrong.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
On TheBodyPRO.com
- Early Virologic Non-Response in Patients With HIV Infection Treated With Lamivudine, Abacavir and Tenofovir (July 25, 2003)
"Dear Healthcare Provider" letter from GlaxoSmithKline.
From U.S. Food and Drug Administration
On TheBodyPRO.com
- Combivir + Abacavir Better Tolerated and More Potent Than Combivir + Nelfinavir (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Substituting AZT or Abacavir for d4T in Patients With Lipoatrophy (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Addition of Abacavir Does Not Appreciably Enhance the Antiviral Potency of a Standard Triple-Therapy Regimen (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Comparison of Once-Daily FTC Vs. Twice-Daily Abacavir in a Regimen for Drug-Naive Patients (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Abacavir/3TC/Tenofovir Combination Failure in Treatment-Naive Patients (July 14, 2003)
Analysis by Timothy Wilkin, M.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Abacavir/3TC/Tenofovir Combination Fails in Treatment-Naive Patients (July 14, 2003)
Analysis by Benjamin Young, M.D., Ph.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from TheBodyPRO.com
- Abacavir Arm Stopped in Clinical Trial (April 4, 2003)
In AIDS Treatment News, from AIDS Treatment News
On TheBodyPRO.com
- Improvements in Body Fat and Mitochondrial DNA Levels Are Accompanied by Decreased Adipose Tissue Cell Apoptosis After Replacement of Stavudine Therapy With Either Abacavir or Zidovudine (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
|
Advertisement
|
Email
Glossary
